<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vestar</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник аритмологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Arrhythmology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-8641</issn><issn pub-type="epub">2658-7327</issn><publisher><publisher-name>НАО «Инкарт»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35336/VA-1518</article-id><article-id custom-type="elpub" pub-id-type="custom">vestar-1535</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Сердечная ресинхронизирующая терапия: путь к персонифицированному выбору устройства. Результаты двухлетнего проспективного исследования</article-title><trans-title-group xml:lang="en"><trans-title>Cardiac resynchronization therapy: towards personalized device selection. Results of a two-year prospective study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7167-4713</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорин</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorin</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зорин Дмитрий Андреевич </p><p>Астрахань, ул. Бакинская, д. 121 </p><p>Астрахань, ул. Покровская Роща, д. 4 </p></bio><bio xml:lang="en"><p>Zorin Dmitry </p><p>Astrakhan, 121 Bakinskaya str. </p><p>Astrakhan, 4 Pokrovskaya Roscha str. </p></bio><email xlink:type="simple">zorin.dmitry.a@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1294-9646</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Илов</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ilov</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Астрахань, ул. Бакинская, д. 121 </p><p>Астрахань, ул. Покровская Роща, д. 4 </p></bio><bio xml:lang="en"><p>Astrakhan, 121 Bakinskaya str. </p><p>Astrakhan, 4 Pokrovskaya Roscha str. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8326-2644</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каримов</surname><given-names>И. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Karimov</surname><given-names>I. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Астрахань, ул. Покровская Роща, д. 4 </p></bio><bio xml:lang="en"><p>Astrakhan, 4 Pokrovskaya Roscha str. </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5722-9883</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нечепуренко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nechepurenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Астрахань, ул. Покровская Роща, д. 4 </p></bio><bio xml:lang="en"><p>Astrakhan, 121 Bakinskaya str. </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8451-9837</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорина</surname><given-names>Н. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Zorina</surname><given-names>N. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Астрахань, ул. Л. Толстого, д. 6 </p></bio><bio xml:lang="en"><p>Astrakhan, 6 L. Tolstoy str. </p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Астраханский ГМУ» Минздрава России; ФГБУ «ФЦССХ» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBEI HE Astrakhan State Medical University of the ЬР КА; FSBI “Federal Center for Cardiovascular Surgery” of the ЬР КА</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «ФЦССХ» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBI “Federal Center for Cardiovascular Surgery” of the ЬР КА</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ АО «Городская поликлиника № 10»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>SBHI of Astrakhan Region “City Polyclinic No. 10”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>06</month><year>2025</year></pub-date><volume>32</volume><issue>2</issue><fpage>52</fpage><lpage>61</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зорин Д.А., Илов Н.Н., Каримов И.Р., Нечепуренко А.А., Зорина Н.П., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Зорин Д.А., Илов Н.Н., Каримов И.Р., Нечепуренко А.А., Зорина Н.П.</copyright-holder><copyright-holder xml:lang="en">Zorin D.A., Ilov N.N., Karimov I.R., Nechepurenko A.A., Zorina N.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestar.elpub.ru/jour/article/view/1535">https://vestar.elpub.ru/jour/article/view/1535</self-uri><abstract><sec><title>Цель</title><p>Цель. Провести сравнительный анализ клинических, инструментальных и лабораторных методов диагностики, установить факторы, определяющие вероятность возникновения устойчивых пароксизмов желудочковых тахиаритмий (ЖТ) у пациентов с показаниями к проведению сердечной ресинхронизирующей терапии (СРТ).</p><p>Материл и методы исследования. В исследование включены 124 пациента с хронической сердечной недостаточностью и имплантированной системой СРТ-Д. Медианный возраст пациентов составил 58 (52-63) лет. Пациенты наблюдались в течение 24 месяцев. Оценивались клинико-демографические характеристики, ЭКГ, параметры спекл-трекинг эхокардиографии, уровень биомаркеров в крови. Конечной точкой служило развитие устойчивых ЖТ, зарегистрированных устройством. Для прогнозирования двухлетней вероятности возникновения ЖТ строилась многовариантная логистическая регрессионная модель</p></sec><sec><title>Результаты</title><p>Результаты. У 29 (23,3%) пациентов в течение наблюдения зафиксированы эпизоды устойчивых ЖТ. При проведении однофакторного анализа было выбрано 7 номинальных факторов с наибольшим потенциалом относительно достижения конечной точки. К ним относились клинические данные (наличие ишемической болезни сердца, фибрилляции предсердий); электрокардиографические критерии (значение модифицированного QRS более 0,6, наличие полной блокады левой ножки пучка Гиса (ПБЛНПГ) по критериям Strauss); эхокардиографические критерии (значение глобального продольного стрейна ≥ минус 6%, наличие умеренной митральной регургитации и более); лабораторные показатели (галектин-3 ≥12 нг/мл). На основании данных показателей с использованием метода бинарной логистической регрессии была разработана прогностическая модель, позволяющая определять двухлетнюю вероятность возникновения ЖТ у больных с показаниями к имплантации устройства для СРТ. В конечную модель не вошел показатель наличия ПБЛНПГ по Strauss, имевший хорошую статистическую значимость при проведении однофакторного анализа. Диагностическая эффективность при точке отсечения значений регрессионной функции 0,228 составила 73,6% (чувствительность - 86,2%, специфичность - 69,6%). Площадь под ROC-кривой, соответствующей взаимосвязи двухлетнего прогноза ЖТ и значения регрессионной функции, составила 0,779, что согласно экспертной шкале для значений AUC соответствует хорошему качеству модели.</p></sec><sec><title>Заключение</title><p>Заключение. Проведённое исследование позволило выявить ряд независимых предикторов риска внезапной сердечной смерти у пациентов с имплантированным СРТ-Д и составить многофакторную прогностическую модель. Полученные данные свидетельствуют о возможности разработки персонализированного алгоритма выбора устройства.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To conduct a comparative analysis of clinical, instrumental, and laboratory diagnostic methods and to identify factors determining the likelihood of sustained paroxysmal ventricular tachyarrhythmias (VT) in patients with indications for cardiac resynchronization therapy (CRT).</p></sec><sec><title>Methods</title><p>Methods. The study included 124 patients with chronic heart failure (CHF) and an implanted CRT-D system. The median age was 58 (52-63) years. Patients were followed for 24 months. Clinical and demographic characteristics, electrocardiographic data, speckle-tracking echocardiographic parameters, and blood biomarker levels were assessed. The primary endpoint was the occurrence of sustained VT episodes recorded by the implanted device. A multivariate logistic regression model was developed to predict the two-year probability of VT occurrence.</p></sec><sec><title>Results</title><p>Results. During the follow-up period, 29 patients (23.3%) experienced episodes of sustained VT. Univariate analysis identified seven candidate predictors with the highest potential for reaching the endpoint. These included: clinical factors (presence of coronary artery disease and atrial fibrillation); ECG parameters (modified QRS index &gt;0.6, presence of left bundle branch block (LBBB) according to Strauss criteria); echocardiographic findings (global longitudinal strain ≥ -6%, mitral regurgitation of grade 2 or higher); and laboratory markers (galectin-3 ≥ 12 ng/mL). Based on these variables, a predictive model was developed using binary logistic regression to estimate the two-year risk of VT in patients with CRT indications. The Strauss LBBB criterion, although statistically significant in univariate analysis, was not included in the final model. At a regression function cut-off value of 0.228, the model demonstrated a diagnostic accuracy of 73.6% (sensitivity - 86.2%, specificity - 69.6%). The area under the ROC curve was 0.779, which, according to expert grading, indicates good model performance.</p></sec><sec><title>Conclusion</title><p>Conclusion. The study identified several independent predictors of sudden cardiac death risk in patients with implanted CRT-D devices and enabled the construction of a multifactorial prognostic model. The findings suggest the potential for developing a personalized algorithm for device selection.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая сердечная недостаточность</kwd><kwd>сердечная ресинхронизирующая терапия</kwd><kwd>желудочковые тахиаритмии</kwd><kwd>стратификация риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure</kwd><kwd>cardiac resynchronization therapy</kwd><kwd>ventricular tachyarrhythmias</kwd><kwd>risk stratification</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardio.l 2024;21: 717-34. https://doi.org/10.1038/s41569-024-01046-6.</mixed-citation><mixed-citation xml:lang="en">Khan MS, Shahid I, Bennis A, et al. Global epidemiology of heart failure. Nat Rev Cardio.l 2024;21: 717-34. https://doi.org/10.1038/s41569-024-01046-6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Постол АС, Неминущий НМ, Антипов ГН и др. Факторы, определившие положительный ответ на ресинхронизирующую терапию у пациентов с хронической сердечной недостаточностью и диссинхронией сердца. Опыт одного центра. Кардиология. 2024;64(7): 31-39. https://doi.org/10.18087/cardio.2024.7.n2627.</mixed-citation><mixed-citation xml:lang="en">Postol AS, Neminushchiy NM, Antipov GN, Ivanchenko AV, et al. Factors that Determined a Positive Response to Resynchronization Therapy in Patients With Chronic Heart Failure and Cardiac Dyssynchrony. One Center Experience. Kardiologiia. 2024;64(7): 31-39. (In Russ.) https://doi.org/10.18087/cardio.2024.7.n2627.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Hear. Eur Heart J. 2021;42: 3427-520. https://doi.org/10.1093/eurheartj/ehab364.</mixed-citation><mixed-citation xml:lang="en">Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Hear. Eur Heart J. 2021;42: 3427-520. https://doi.org/10.1093/eurheartj/ehab364.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев ДС, Михайлов ЕН, Неминущий НМ, и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7): 4600. https://doi:10.15829/1560-4071-2021-4600.</mixed-citation><mixed-citation xml:lang="en">Lebedev DS, Mikhailov EN, Neminuschiy NM, еt al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021;26(7): 4600. (In Russ.). https://doi:10.15829/1560-4071-2021-4600.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barra S, Providência R, Boveda S, et al. Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart. 2018;104: 1529-35. https://doi.org/10.1136/heartjnl-2017-312546.</mixed-citation><mixed-citation xml:lang="en">Barra S, Providência R, Boveda S, et al. Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart. 2018;104: 1529-35. https://doi.org/10.1136/heartjnl-2017-312546.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Devesa Neto V, Costa G, Santos LF, et al. Systematic review and meta-analysis comparing cardiac resynchronization therapy with versus without defibrillation in patients with non-ischemic cardiomyopathy. EP Eur. 2024;26: euae102.488. https://doi.org/10.1093/europace/euae102.488.</mixed-citation><mixed-citation xml:lang="en">Devesa Neto V, Costa G, Santos LF, et al. Systematic review and meta-analysis comparing cardiac resynchronization therapy with versus without defibrillation in patients with non-ischemic cardiomyopathy. EP Eur. 2024;26: euae102.488. https://doi.org/10.1093/europace/euae102.488.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Терещенко СН, Галявич АС, Ускач ТМ, и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11): 4083. https://doi:10.15829/1560-4071-2020-4083.</mixed-citation><mixed-citation xml:lang="en">Tereshchenko SN, Galyavich AS, Uskach TM, et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11): 4083. (In Russ.). https://doi:10.15829/1560-4071-2020-4083.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Krueger S, Kass DA, Marco T De, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure 2004:2140-50.</mixed-citation><mixed-citation xml:lang="en">Krueger S, Kass DA, Marco T De, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure 2004:2140-50.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J. 2021;42: 1676-84. https://doi.org/10.1093/eurheartj/ehaa1057.</mixed-citation><mixed-citation xml:lang="en">Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J. 2021;42: 1676-84. https://doi.org/10.1093/eurheartj/ehaa1057.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Базылев ВВ, Ушаков РЮ, Дурманов СС и др. Прогностическое значение отсроченного накопления гадолиния при магнитно-резонансной томографии сердца у больных с ишемической кардиомиопатией и имплантированным кардиовертером-дефибриллятором. Вестник Аритмологии. 2024;2: 35-43. https://doi.org/https://doi.org/10.35336/VA-1260.</mixed-citation><mixed-citation xml:lang="en">Bazylev VV, Ushakov RYu, Durmanov SS, et al. Prognostic value of delayed gadolinium enhancement on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy and an implanted cardioverter-defibrillator. Journal of Arrhythmology. 2024;31(2): 35-43 (in Russ). https://doi.org/https://doi.org/10.35336/VA-1260.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43: 3997-4126. https://doi.org/10.1093/eurheartj/ehac262.</mixed-citation><mixed-citation xml:lang="en">Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43: 3997-4126. https://doi.org/10.1093/eurheartj/ehac262.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Varma N, Lappe J, He J, Niebauer M, et al. Sex-Specific Response to Cardiac Resynchronization Therapy: Effect of Left Ventricular Size and QRS Duration in Left Bundle Branch Block. JACC Clin Electrophysiol. 2017;3: 844-53. https://doi.org/10.1016/j.jacep.2017.02.021.</mixed-citation><mixed-citation xml:lang="en">Varma N, Lappe J, He J, Niebauer M, et al. Sex-Specific Response to Cardiac Resynchronization Therapy: Effect of Left Ventricular Size and QRS Duration in Left Bundle Branch Block. JACC Clin Electrophysiol. 2017;3: 844-53. https://doi.org/10.1016/j.jacep.2017.02.021.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Frodi DM, Diederichsen SZ, Xing LY, et al. Incidence and risk factors for first and recurrent ICD shock therapy in patients with an implantable cardioverter defibrillator. J Interv Card Electrophysiol. 2025;68: 125-39. https://doi.org/10.1007/s10840-024-01873-0.</mixed-citation><mixed-citation xml:lang="en">Frodi DM, Diederichsen SZ, Xing LY, et al. Incidence and risk factors for first and recurrent ICD shock therapy in patients with an implantable cardioverter defibrillator. J Interv Card Electrophysiol. 2025;68: 125-39. https://doi.org/10.1007/s10840-024-01873-0.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361: 1329-38. https://doi.org/10.1056/NEJMoa0906431.</mixed-citation><mixed-citation xml:lang="en">Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361: 1329-38. https://doi.org/10.1056/NEJMoa0906431.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Fan X, Li S, et al. A Novel Risk Stratification Score for Sudden Cardiac Death Prediction in Middle-Aged, Nonischemic Dilated Cardiomyopathy Patients: The ESTIMATED Score. Can J Cardiol. 2020;36: 1121-9. https://doi.org/10.1016/j.cjca.2019.11.009.</mixed-citation><mixed-citation xml:lang="en">Li X, Fan X, Li S, et al. A Novel Risk Stratification Score for Sudden Cardiac Death Prediction in Middle-Aged, Nonischemic Dilated Cardiomyopathy Patients: The ESTIMATED Score. Can J Cardiol. 2020;36: 1121-9. https://doi.org/10.1016/j.cjca.2019.11.009.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Reeder HT, Shen C, Buxton AE, et al. Joint Shock/ Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators. Circ Cardiovasc Qual Outcomes. 2019;12:e005675. https://doi.org/10.1161/CIRCOUTCOMES.119.005675.</mixed-citation><mixed-citation xml:lang="en">Reeder HT, Shen C, Buxton AE, et al. Joint Shock/ Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators. Circ Cardiovasc Qual Outcomes. 2019;12:e005675. https://doi.org/10.1161/CIRCOUTCOMES.119.005675.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116: 392-8. https://doi. org/10.1161/CIRCULATIONAHA.106.687103.</mixed-citation><mixed-citation xml:lang="en">Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116: 392-8. https://doi. org/10.1161/CIRCULATIONAHA.106.687103.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ido G, K. AM, Wojciech Z, et al. QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients. JACC Clin Electrophysiol. 2024;10: 16-26. https://doi.org/10.1016/j.jacep.2023.09.018.</mixed-citation><mixed-citation xml:lang="en">Ido G, K. AM, Wojciech Z, et al. QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients. JACC Clin Electrophysiol. 2024;10: 16-26. https://doi.org/10.1016/j.jacep.2023.09.018.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Илов НН, Стомпель ДР, Пальникова ОВ, Нечепуренко АА. Выбор эхокардиографического показателя для оценки разных эффектов сердечной ресинхронизирующей терапии. Кардиология и сердечно-сосудистая хирургия. 2022;15(1):19-25. [Ilov NN, Stompel DR, Palnikova OV, Nechepurenko AA. Echocardiography parameter for evaluation of various effects of cardiac resynchronization therapy. Russian Journal of Cardiology and Cardiovascular Surgery. 2022;15(1): 19‑25. (In Russ.)] https://doi.org/10.17116/kardio20221501119.</mixed-citation><mixed-citation xml:lang="en">Ilov NN, Stompel DR, Palnikova OV, Nechepurenko AA. Echocardiography parameter for evaluation of various effects of cardiac resynchronization therapy. Russian Journal of Cardiology and Cardiovascular Surgery. 2022;15(1): 19‑25. (In Russ.) https://doi.org/10.17116/kardio20221501119.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lai Y, Yoshimura H, Zakkak N, et al. Causes of death in patients with atrial fibrillation in the UK: a nationwide electronic health record study. Eur Hear J Open. 2024;5: oeae103. https://doi.org/10.1093/ehjopen/oeae103.</mixed-citation><mixed-citation xml:lang="en">Lai Y, Yoshimura H, Zakkak N, et al. Causes of death in patients with atrial fibrillation in the UK: a nationwide electronic health record study. Eur Hear J Open. 2024;5: oeae103. https://doi.org/10.1093/ehjopen/oeae103.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Fawzy AM, Bisson A, Bodin A, et al. Atrial Fibrillation and the Risk of Ventricular Arrhythmias and Cardiac Arrest: A Nationwide Population-Based Study. J Clin Med. 2023;12. https://doi.org/10.3390/jcm12031075.</mixed-citation><mixed-citation xml:lang="en">Fawzy AM, Bisson A, Bodin A, et al. Atrial Fibrillation and the Risk of Ventricular Arrhythmias and Cardiac Arrest: A Nationwide Population-Based Study. J Clin Med. 2023;12. https://doi.org/10.3390/jcm12031075.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dzeshka MS, Lip GYH, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. J Am Coll Cardiol. 2015;66: 943-59. https://doi.org/10.1016/j. jacc.2015.06.1313.</mixed-citation><mixed-citation xml:lang="en">Dzeshka MS, Lip GYH, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. J Am Coll Cardiol. 2015;66: 943-59. https://doi.org/10.1016/j. jacc.2015.06.1313.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Centurión OA, Scavenius KE, García LB, et al. Atrioventricular nodal catheter ablation in atrial fibrillation complicating congestive heart failure. J Atr Fibrillation. 2018;11: 1-8. https://doi.org/10.4022/jafib.2013.</mixed-citation><mixed-citation xml:lang="en">Centurión OA, Scavenius KE, García LB, et al. Atrioventricular nodal catheter ablation in atrial fibrillation complicating congestive heart failure. J Atr Fibrillation. 2018;11: 1-8. https://doi.org/10.4022/jafib.2013.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jaiswal V, Taha AM, Joshi A, et al. Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis. Curr Probl Cardiol. 2024;49: 102198. https://doi.org/10.1016/j.cpcardiol.2023.102198.</mixed-citation><mixed-citation xml:lang="en">Jaiswal V, Taha AM, Joshi A, et al. Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis. Curr Probl Cardiol. 2024;49: 102198. https://doi.org/10.1016/j.cpcardiol.2023.102198.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Amoni M, Dries E, Ingelaere S, et al. Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment. Cells. 2021;10. https://doi. org/10.3390/cells10102629. 26. Masarone D, Limongelli G, Ammendola E, et al. Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update. J Clin Med. 2018;7. https://doi.org/10.3390/jcm7110436.</mixed-citation><mixed-citation xml:lang="en">Amoni M, Dries E, Ingelaere S, et al. Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment. Cells. 2021;10. https://doi. org/10.3390/cells10102629. 26. Masarone D, Limongelli G, Ammendola E, et al. Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update. J Clin Med. 2018;7. https://doi.org/10.3390/jcm7110436.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart RA, Young AA, Anderson C, et al. Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk. Heart. 2011;97: 1766-70. https://doi.org/10.1136/heartjnl-2011-300297.</mixed-citation><mixed-citation xml:lang="en">Stewart RA, Young AA, Anderson C, et al. Relationship between QRS duration and left ventricular mass and volume in patients at high cardiovascular risk. Heart. 2011;97: 1766-70. https://doi.org/10.1136/heartjnl-2011-300297.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Michalski B, Stankovic I, Pagourelias E, et al. Relationship of Mechanical Dyssynchrony and LV Remodeling With Improvement of Mitral Regurgitation After CRT. JACC Cardiovasc Imaging. 2022;15: 212-20. https://doi.org/10.1016/j.jcmg.2021.08.010.</mixed-citation><mixed-citation xml:lang="en">Michalski B, Stankovic I, Pagourelias E, et al. Relationship of Mechanical Dyssynchrony and LV Remodeling With Improvement of Mitral Regurgitation After CRT. JACC Cardiovasc Imaging. 2022;15: 212-20. https://doi.org/10.1016/j.jcmg.2021.08.010.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Medvedofsky D, Arany-Lao-Kan G, McNitt S, et al. Predictive value of global longitudinal strain by left ventricular ejection fraction. ESC Hear Fail. 2023;10: 1937- 47. https://doi.org/https://doi.org/10.1002/ehf2.14193.</mixed-citation><mixed-citation xml:lang="en">Medvedofsky D, Arany-Lao-Kan G, McNitt S, et al. Predictive value of global longitudinal strain by left ventricular ejection fraction. ESC Hear Fail. 2023;10: 1937- 47. https://doi.org/https://doi.org/10.1002/ehf2.14193.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jang SY. Application of Global Longitudinal Strain as a Parameter of Left Ventricular Systolic Function in Echocardiography. Clin Ultrasound. 2023;8: 53-8. https://doi. org/10.18525/cu.2023.8.2.53.</mixed-citation><mixed-citation xml:lang="en">Jang SY. Application of Global Longitudinal Strain as a Parameter of Left Ventricular Systolic Function in Echocardiography. Clin Ultrasound. 2023;8: 53-8. https://doi. org/10.18525/cu.2023.8.2.53.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Nikoo MH, Naeemi R, Moaref A, Attar A. Global longitudinal strain for prediction of ventricular arrhythmia in patients with heart failure. ESC Hear Fail. 2020;7: 2956- 61. https://doi.org/10.1002/ehf2.12910.</mixed-citation><mixed-citation xml:lang="en">Nikoo MH, Naeemi R, Moaref A, Attar A. Global longitudinal strain for prediction of ventricular arrhythmia in patients with heart failure. ESC Hear Fail. 2020;7: 2956- 61. https://doi.org/10.1002/ehf2.12910.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Biering-Sørensen T, Knappe D, Pouleur A-C, et al. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction. Circ Cardiovasc Imaging. 2017;10: e005096. https://doi.org/10.1161/CIRCIMAGING.116.005096.</mixed-citation><mixed-citation xml:lang="en">Biering-Sørensen T, Knappe D, Pouleur A-C, et al. Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction. Circ Cardiovasc Imaging. 2017;10: e005096. https://doi.org/10.1161/CIRCIMAGING.116.005096.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Andrès N, Rossignol P, Iraqi W, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14: 74-81. https://doi.org/10.1093/eurjhf/hfr151.</mixed-citation><mixed-citation xml:lang="en">Lopez-Andrès N, Rossignol P, Iraqi W, et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14: 74-81. https://doi.org/10.1093/eurjhf/hfr151.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Makimoto H, Müller P, Denise K, et al. Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators. Intern Med 2022;61: 969- 77. https://doi.org/10.2169/internalmedicine.7886-21.</mixed-citation><mixed-citation xml:lang="en">Makimoto H, Müller P, Denise K, et al. Clinical Impact of Circulating Galectin-3 on Ventricular Arrhythmias and Heart Failure Hospitalization Independent of Prior Ventricular Arrhythmic Events in Patients with Implantable Cardioverter-defibrillators. Intern Med 2022;61: 969- 77. https://doi.org/10.2169/internalmedicine.7886-21.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zaborska B, Sikora-Frąc M, Smarż K, et al. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms241713111.</mixed-citation><mixed-citation xml:lang="en">Zaborska B, Sikora-Frąc M, Smarż K, et al. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms241713111.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
